Sugi Predict

Sugi Predict / Compounds / SCHEMBL5063172

SCHEMBL5063172

SCHEMBL5063172

NC(=O)CC[C@H](N)C(=O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ P2RY1 P47900 7/20 0.71
▸ P2RY2 P41231 3/20 0.71
▸ SRC P12931 2/20 0.71
▸ SMN1; SMN2 Q16637 2/20 0.71
▸ P2RX1 P51575 2/20 0.71
▸ P2RX3 P56373 2/20 0.71
▸ ALDH1A1 P00352 2/20 0.71
▸ P2RX4 Q99571 1/20 0.71
▸ P2RX2 Q9UBL9 1/20 0.71
▸ QARS1 P47897 2/20 0.69
▸ TRPM2 O94759 2/20 0.68
▸ TAS1R3 Q7RTX0 2/20 0.68
▸ TAS1R1 Q7RTX1 2/20 0.68
▸ DNPH1 O43598 1/20 0.68
▸ PRKAB2 O43741 1/20 0.68
▸ LDHA P00338 1/20 0.68
▸ ADRB2 P07550 1/20 0.68
▸ FBP1 P09467 1/20 0.68
▸ ADORA1 P30542 1/20 0.68
▸ PRKAG1 P54619 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30151699 0.90 P2RY1 (0.70) P2RY1P2RY2SRCSMN1; SMN2P2RX1
Adenosine Phosphate SCHEMBL7225652 0.89 P2RY1 (0.77) P2RY1P2RY2SRCSMN1; SMN2P2RX1
Adenosine Phosphate SCHEMBL15670721 0.89 P2RY1 (0.77) P2RY1P2RY2SRCSMN1; SMN2P2RX1
SCHEMBL5067246 0.89 RARS1 (0.78) P2RY1P2RY2SRCSMN1; SMN2P2RX1
SCHEMBL18423487 0.89 P2RY1 (0.73) P2RY1P2RY2SRCSMN1; SMN2P2RX1
SCHEMBL28319431 0.87 P2RY1 (0.82) P2RY1P2RY2SRCSMN1; SMN2P2RX1
SCHEMBL31429803 0.86 EZH2 (0.71) P2RY1P2RY2SRCSMN1; SMN2P2RX1
SCHEMBL4945718 0.86 P2RY1 (0.69) P2RY1P2RY2SRCSMN1; SMN2P2RX1
SCHEMBL30051599 0.86 P2RY1 (0.69) P2RY1P2RY2SRCSMN1; SMN2P2RX1
SCHEMBL3046222 0.85 P2RY1 (0.92) P2RY1P2RY2SRCSMN1; SMN2P2RX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080318884-A1 Methods for Altering Gene Expression and Methods of Treatment Utilizing Same THE UAB RESEARCH FOUNDATION (US) 2008-12-25 — — US claimed
WO-2006105038-A2 METHODS OF ALTERING GENE EXPRESSION AND METHODS OF TREATMENT UTILIZING SAME THE UAB RESEARCH FOUNDATION (US) 2006-10-05 — — WO claimed
WO-2016201374-A1 SULFANIDE ADENOSINE DERIVATIVES AND USES THEREOF UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2016-12-15 — — WO disclosed
US-20080318884-A1 Methods for Altering Gene Expression and Methods of Treatment Utilizing Same THE UAB RESEARCH FOUNDATION (US) 2008-12-25 — — US disclosed
WO-2006105038-A2 METHODS OF ALTERING GENE EXPRESSION AND METHODS OF TREATMENT UTILIZING SAME THE UAB RESEARCH FOUNDATION (US) 2006-10-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318884-A1 Methods for Altering Gene Expression and Methods of Treatment Utilizing Same TRDMT1, TARBP1, TRMT1 P2RY1 4627/4885P2RY2 4285/4885SRC 4573/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.